Back to search

Netherlands· NL-7f7cce2fef71

Dovato 50 mg/300 mg filmomhulde tabletten

A lamivudine and dolutegravir product containing dolutegravir natrium + lamivudine 0-water, registered in Netherlands by ViiV healthcare B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR25

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDovato 50 mg/300 mg filmomhulde table…ATCJ05AR25REGISTER NO.NL-7f7cce2fef71PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Lamivudine and dolutegravir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR25 (lamivudine and dolutegravir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Lamivudine and dolutegravir · ATC J05AR25

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
DOLUTEGRAVIR NATRIUM + LAMIVUDINE 0-WATER
Manufacturer
ViiV healthcare B.V.
Country
Netherlands (NL)
ATC code
J05AR25
ATC class
Lamivudine and dolutegravir
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/19/1370

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Lamivudine and dolutegravir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine and dolutegravir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Dovato
  • Liechtenstein · Dovato
  • Norway · Dovato

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5cff55d4-7ccb-4312-b8b9-5851f489babd
GET /v1/drugs/5cff55d4-7ccb-4312-b8b9-5851f489babd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lamivudine and dolutegravir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp123802",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "MACROGOL 400",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "NATRIUMSTEARYLFUMARAAT",
    "NATRIUMZETMEELGLYCOLAAT",
    "POVIDON K 30 (E 1201)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "DOLUTEGRAVIR NATRIUM",
    "LAMIVUDINE 0-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2019/07/01",
  "procedure_number": "EMEA/H/C/004909",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1370",
  "additional_monitoring": "Y"
}

See everything about lamivudine and dolutegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.